Phase 2 Asthma Trial, Recruiting NCT05259904 Sponsor: University of Colorado, Denver Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT05259904
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have completed the consent process and signed the required paperwork
  • Men and women between 18 and 70 years old (inclusive)
  • People who developed ongoing breathing symptoms — such as cough, shortness of breath, wheezing, and/or chest tightness — during or after military deployment to Southwest Asia after 9/11/2001, and whose breathing test results meet specific criteria for deployment-related asthma (confirm with trial site for full details on accepted test results)
  • People who are able to perform breathing tests reliably according to standard guidelines
  • People of any racial or ethnic background
  • People with a smoking history of 15 pack-years or less, and who have not smoked in the last 3 months
  • People whose asthma is not well controlled at the start of the trial, based on standard asthma questionnaire scores (confirm with trial site)

Who may not be able to join:

  • People who have had a respiratory tract infection in the 4 weeks before the first visit
  • People who have had an emergency department visit for a lung-related reason in the 4 weeks before the first visit
  • People who have taken a course of oral or systemic steroid medication for any reason in the 4 weeks before the first visit (single-dose injections into a joint require a 2-week gap before the first visit)
  • People with significant other medical conditions — such as heart disease, cancer, uncontrolled diabetes, or other chronic lung diseases — as determined by the lead investigator
  • People with chronic kidney failure above a certain level, identified by a blood test at the first visit
  • People who are pregnant, or who test positive for pregnancy at any point during the study
  • People with a known intolerance or allergy to L-arginine or L-citrulline (the study supplements)
  • People currently taking a class of medications called PDE5 inhibitors or oral mononitrates (confirm with trial site if unsure whether a current medication falls into these categories)
  • People who, in the investigator's opinion, are unlikely to be able to complete all study requirements
  • People for whom, in the investigator's opinion, taking part would carry too much personal health risk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fernando Holguin, MD, MPH, University of Colorado Denver- Anschutz Medical Campus

Phone: 1-844-365-0852

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 March 2023
Est. completion
1 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Asthma Control Questionnaire; Change in FeNO values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov